A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions

Cancer Medicine

Volumn 4, Issue 1, 2015, Pages 36-42

  Maier, Sabine ^a   Chung, Christine H ^b   Morse, Michael ^c   Platts Mills, Thomas ^d   Townes, Leigh ^a   Mukhopadhyay, Pralay ^a   Bhagavatheeswaran, Prabhu ^a   Racenberg, Jan ^a   Trifan, Ovidiu C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Biomarkers; Cetuximab; Colorectal neoplasms; Head and neck neoplasms; Immunoglobulin E; Lung neoplasms

Indexed keywords

CETUXIMAB; CROSS REACTING ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER PATIENT; HIGH RISK PATIENT; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; CROSS REACTION; DRUG HYPERSENSITIVITY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; ODDS RATIO; RETROSPECTIVE STUDY; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CETUXIMAB; CROSS REACTIONS; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOGLOBULIN E; INFUSIONS, INTRAVENOUS; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85005773724     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.333     Document Type: Article

References (16)

1. Herceptin (trastuzumab) [package insert]. 2014. Genentech, Inc, South San Francisco, CA.
2. Rituxan (rituximab) [package insert]. 2013. Genentech, Inc, South San Francisco, CA.
3. Avastin (bevacizumab) [package insert]. 2013. Genentech, Inc, South San Francisco, CA.
4. Remicade (infliximab) [package insert]. 2013. Janssen Biotech, Inc, Horsham, PA.
5. Erbitux (cetuximab) [package insert]. 2004-2013. ImClone, a wholly-owned subsidiary of Eli Lilly and Company and Bristol-Myers Squibb Company, Branchburg, NJ, and Princeton, NJ.
6. Vectibix (panitumumab) [package insert]. 2013. Amgen Inc, Thousand Oaks, CA.
7. Pichler, W. J. 2007. Drug hypersensitivity reactions: classification and relationship to T-cell activation. Pp. 168-189 in W. J. Pichler, ed. Drug hypersensitivity. Karger, Basel, Switzerland.
8. O'Neil, B. H., R. Allen, D. R. Spigel, T. E. Stinchcombe, D. T. Moore, J. D. Berlin, et al. 2007. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J. Clin. Oncol. 25:3644-3648.
9. Kiwan, E. N., E. Siegel, L. F. Hutchins, A. Maddox, R. Govindarajan, A. M. Safar, et al. 2011. Cetuximab-related infusion reaction rate in cancer patients differs by race [abstract]. J. Clin. Oncol. 29(Suppl.):e14075 Abstract.
10. Owera, R., A. Gill, S. Haddadin, R. Khozouz, and M. C. Perry . 2008. High incidence of hypersensitivity reactions to cetuximab in fusions in mid-Missouri: association with prior history of atopy [abstract]. J. Clin. Oncol. 26(Suppl.):20747 Abstract.
11. Chung, C. H., B. Mirakhur, E. Chan, Q. T. Le, J. Berlin, M. Morse, et al. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N. Engl. J. Med. 358:1109-1117.
12. Commins, S. P., H. R. James, L. A. Kelly, S. L. Pochan, L. J. Workman, M. S. Perzanowski, et al. 2011. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1, 3-galactose. J. Allergy Clin. Immunol. 127:1286-1293.
13. Commins, S. P., S. M. Satinover, J. Hosen, J. Mozena, L. Borish, B. D. Lewis, et al. 2009. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1, 3-galactose. J. Allergy Clin. Immunol. 123:426-433.
14. Yman, L. 1991. Standardization of IgE antibody assays. J. Int. Fed. Clin. Chem. 3:198-203.
15. Yman, L. 2001. Allergy. Pp. 664-680 in D. Wild, ed. The immunoassay handbook. Nature Publishing Group, New York, NY.
16. Mariotte, D., B. DuPont, R. Gervais, M. P. Galais, D. Laroche, A. Tranchant, et al. 2011. Anti-cetuximab IgE ELISA for identification of patients at high risk of cetuximab-induced anaphylaxis. MAbs 3:396-401.